TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01771874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: 125 mg per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion will be administered in a dose of 150mg (Wellbutrin XR) once-daily in the morning for three days followed by 300mg (2x150mg) for 4 days before the test day. On the test day, a final dose of 300mg will administered 2 hours before the administration of MDMA 125 mg or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: per os
Study: NCT01079325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-509
Description: SB-509 60 mg, 3 treatments, and 5 months treatment period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02847169

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filcon IV1 toric lens
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ocufilcon D toric lens
Description: toric contact lens
Study: NCT03670849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LapAR
Description: LapAR system will map (transform) the live LUS image in the reference frame of the laparoscopic camera, and fuse it with the live laparoscopic video in real time. For thermal ablations that involve a needle, we also track the needle and overlay its path on the AR view.
Study: NCT01178736

Intervention type: PROCEDURE
Intervention: Endometrial Cancer Screening and Diagnosis
Description: Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.
Study: NCT00994903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40mg orally, given 3-7 days pre-op and continued till 14 days post-op

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
Study: NCT04396821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 is a humanized IgG1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 is a humanized IgG1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 is a humanized IgG1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 is a humanized IgG1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 is a humanized IgG1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies
Study: NCT04453722

Intervention type: DEVICE
Intervention: Oxalert Monitor Mode
Description: The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO. Using the Oxalert in monitor only mode.

Intervention type: DEVICE
Intervention: Oxalert Normal mode
Description: The investigator will evaluate the feasibility of a fully randomized validation trial for the Oxalert EPO using the Oxalert in monitor in normal mode
Study: NCT01061411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT04396821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab is one of the PD-1 checkpoint inhibitors, and has proved clinical benefit for multiple late-stage malignancies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 is a combination chemotherapy regimen including the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy medication
Study: NCT03366038

Intervention type: PROCEDURE
Intervention: Shark Mouth Modified Pancreaticojejunostomy
Description: The remnant of jejunum is closed by continuous suture. The transverse incision is made on the posterior wall of the jejunum (5 centimeters distal to remnant）, which starts at 0.2 centimeter to the mesenteric border and should never exceed the anti-mesenteric border . In case of large pancreas remnant, a longitudinal jejunum incision will be done at anterior part of anastomosis.~The posterior part of anastomosis is two layers of intermittent suture, including seromuscular suture layer and full thickness suture layer. The anterior part of anastomosis is a single layer full thickness suture. At last, the seromuscular layer of the proximal jejunum is sutured with the anterior pancreatic capsule to cover the anterior part of anastomosis.
Study: NCT00517335

Intervention type: PROCEDURE
Intervention: Functional magnetic resonance imaging (fMRI) scan
Description: Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.

Intervention type: PROCEDURE
Intervention: Functional magnetic resonance imaging (fMRI) scan
Description: Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
Study: NCT04396821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Chemotherapy medication
Study: NCT00517335

Intervention type: PROCEDURE
Intervention: Functional magnetic resonance imaging (fMRI) scan
Description: Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
Study: NCT01647646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide
Description: Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
Study: NCT02691221

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relief Link Application Daily Tasks
Description: Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
Study: NCT03560635

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Maintenance (Control vs. Reverse Diet)
Description: Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Maintenance (Control vs. Reverse Diet)
Description: Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
Study: NCT02887859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Acellular Vessel (HAV)
Description: Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques
Study: NCT03496129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback
Description: Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback and text messages
Description: Experimental: Personalized feedback and text messages~Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Only
Description: Active Comparator: Information Only~Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
Study: NCT04046341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Well!
Description: The intervention comprehensively addresses poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers. Interventionists will use strategies to engage with and empower families, such as motivational interviewing and collaborative problem-solving. Session content will be reinforced via phone calls from interventionists. Families will receive intervention session appointment reminders and information about intervention content (e.g., reminders to follow a bedtime routine) via text message.
Study: NCT02322268

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cosmos Caudatus
Description: 15g of Cosmos caudatus consumed with lunch or dinner
Study: NCT04328233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating
Description: Participants will reduce the amount of time they eat to 10 hours per day over a 12-week monitored intervention followed by a 12-week self-directed intervention and will log their dietary intake using a smartphone application (mCC app). The participants will select a 10-h eating window that best suits their lifestyle. All food/beverages except water must be consumed within the time-interval. No further dietary restrictions will be applied. The participants will be provided with behavioral nutritional counseling by a dietician.
Study: NCT02850952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehab MATRIX
Description: Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
Study: NCT03941483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1128
Description: Intravenous Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Infusion
Study: NCT02114177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: 150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 12 weeks in Arm 1.
Study: NCT01313208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Administered by subcutaneous injection once weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: etanercept
Description: Administered by subcutaneous injection once weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARD Therapy
Description: Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMARD Therapy
Description: Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
Study: NCT04518982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab and lenalidomide
Description: Drug: Sintilimab 200mg ivgtt on day 1. Drug: lenalidomide 10mg orally once a day, day 1-14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sintilimab placebo and lenalidomide placebo
Description: Drug: Sintilimab placebo ivgtt on day 1. Drug: lenalidomide placebo orally once a day, day 1-14.
Study: NCT01383967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: Administered orally
Study: NCT01647646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide
Description: Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
Study: NCT01131611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBPT
Description: Cognitive-Behavioral Based Physical Therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control-Attention
Description: Standard of Care + weekly phone calls
Study: NCT01383967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered orally
Study: NCT00593840

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Study: NCT02596152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mini-trampoline
Description: Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
Study: NCT02114177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: 150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 8 weeks in Arm 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks in Arm 2.
Study: NCT03929003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspired
Description: The investigators will be studying the ability of using videogame-based rewards to increase smoking abstinence when they are made contingent on meeting abstinence goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inspired
Description: The investigators will be studying the ability of using videogame-based rewards to increase smoking abstinence when they are made contingent on meeting abstinence goals.
Study: NCT03714438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicago Sativa
Description: Single oral doses of Medicago sativa (1,500 mg), 30 min before before the oral glucose tolerance test.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral doses of placebo (1,500 mg), 30 min before before the oral glucose tolerance test.
Study: NCT02088125

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breath Stacking
Description: Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Spirometry
Description: The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
Study: NCT01464749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-oriented circuit class training
Description: 5 sessions/week over 2 weeks (10 sessions) 120 minutes/each

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: no specific rehabilitation
Study: NCT01850953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: This is an approved smoking cessation medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03919565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b
Description: Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
Study: NCT01790607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2745 /CNS 7056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2745 /CNS 7056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2745 /CNS 7056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2745 /CNS 7056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2745 /CNS 7056
Study: NCT03199677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is an oral tyrosine kinase inhibitor.
Study: NCT03368781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcQMap Imaging and Mapping System
Description: 3D Cardiac Imaging and Mapping during ablation procedures
Study: NCT02560220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mitomycin C-induced peripheral blood mononuclear cells (MICs)
Description: MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
Study: NCT03273686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discharge the NG tube during the surgery
Description: Discharge the NG tube during the surgery.
Study: NCT03904134

Intervention type: OTHER
Group type: OTHER
Intervention: Donor Search Prognosis Score
Description: Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.

Intervention type: OTHER
Group type: OTHER
Intervention: Donor Search Prognosis Score
Description: Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.

Intervention type: OTHER
Group type: OTHER
Intervention: Donor Search Prognosis Score
Description: Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.
Study: NCT02596152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic Walking
Description: Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
Study: NCT00889681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Front Cardiac Cryoablation System
Description: The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.